GSK4024484
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Malaria: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| GSK4024484: this drug | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ganaplacide / Lumefantrine | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Cipargamin | Phase 2 | Small molecule | PfATP4 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK3772701 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| INE963 | Phase 1(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4425689 | —(overall) | Undisclosed | Circumsporozoite protein (CSP) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.